Vion Pharmaceuticals Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New Haven CT United States (1992)
Status: Defunct (2009)

Organization Overview

First Clinical Trial
1998
NCT00004213
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Central Nervous System Neoplasms (Phase 1)

Glioma (Phase 1)

Intestinal Neoplasms (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Myelodysplastic-Myeloproliferative Diseases (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Nervous System Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Preleukemia (Phase 2)

Prostatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 15